trending Market Intelligence /marketintelligence/en/news-insights/trending/dexhumecoxexmlac9t_zow2 content esgSubNav
In This List

Altimmune no longer compliant with Nasdaq listing rule

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Altimmune no longer compliant with Nasdaq listing rule

Altimmune Inc. said it was no longer compliant with Nasdaq's $1 minimum bid price listing requirement.

The Gaithersburg, Md.-based biotechnology company has until Nov. 13 to regain compliance for which its stock price must close at $1 per share for 10 consecutive business days.